Andrea C Lo1,2, Ben Chen3, Vanessa Samuel3, Kerry J Savage3,4,5, Ciara Freeman3,4,5, Karen Goddard6,3. 1. Department of Radiation Oncology, British Columbia (BC) Cancer, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. Andrea.Lo@bccancer.bc.ca. 2. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Andrea.Lo@bccancer.bc.ca. 3. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 4. Centre of Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada. 5. Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada. 6. Department of Radiation Oncology, British Columbia (BC) Cancer, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
Abstract
PURPOSE: The study objective is to describe and quantify the incidence of treatment-induced late effects in AYA lymphoma patients. METHODS: Consecutive patients diagnosed with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) at 15-24 years of age were identified. All patients in British Columbia who received radiation therapy (RT) from 1974 to 2014 with ≥ 5-year survival post-RT were included. Late effects' analyses included only survivors who received RT to the relevant anatomical site(s) and/or relevant chemotherapy, and were reported as cumulative incidence (CI) ± standard error. RESULTS: Three hundred and five patients were identified (74% HL). Median age of diagnosis was 21 years. Median follow-up was 19.1 years for secondary malignancy and 7.2 years for other endpoints. Hypothyroidism was the most prevalent late effect, with a CI of 22.4 ± 2.8% and 35.1 ± 4% at 5 and 10 years, respectively. CI of in-field secondary malignancy was 0.4 ± 0.4% at 10 years and 2.8 ± 1.2% at 20 years. CI of symptomatic pulmonary toxicity was 4.6 ± 1.5% and 6.8 ± 2.0% at 5 and 10 years, respectively, and was higher in patients receiving multiple RT courses (p = 0.009). Esophageal complications occurred at a CI of 1.4 ± 0.8% at 5 years and 2.2 ± 1.1% at 10 years. CI of xerostomia/dental decay was 2.6 ± 1.3% at 5 years and 4.9 ± 2.1% at 10 years. CI of cardiac disease was at 2.3 ± 0.9% at 5 years and 4.4 ± 1.5% at 10 years. CI of infertility was 6.5 ± 1.6% at 5 years and 9.4 ± 2.1% at 10 years. CONCLUSION: Survivors of AYA lymphoma have a high incidence and diverse presentation of late effects. IMPLICATIONS FOR CANCER SURVIVORS: AYA lymphoma survivors should be educated about their risks of late effects and offered screening and follow-up when appropriate.
PURPOSE: The study objective is to describe and quantify the incidence of treatment-induced late effects in AYA lymphoma patients. METHODS: Consecutive patients diagnosed with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) at 15-24 years of age were identified. All patients in British Columbia who received radiation therapy (RT) from 1974 to 2014 with ≥ 5-year survival post-RT were included. Late effects' analyses included only survivors who received RT to the relevant anatomical site(s) and/or relevant chemotherapy, and were reported as cumulative incidence (CI) ± standard error. RESULTS: Three hundred and five patients were identified (74% HL). Median age of diagnosis was 21 years. Median follow-up was 19.1 years for secondary malignancy and 7.2 years for other endpoints. Hypothyroidism was the most prevalent late effect, with a CI of 22.4 ± 2.8% and 35.1 ± 4% at 5 and 10 years, respectively. CI of in-field secondary malignancy was 0.4 ± 0.4% at 10 years and 2.8 ± 1.2% at 20 years. CI of symptomatic pulmonary toxicity was 4.6 ± 1.5% and 6.8 ± 2.0% at 5 and 10 years, respectively, and was higher in patients receiving multiple RT courses (p = 0.009). Esophageal complications occurred at a CI of 1.4 ± 0.8% at 5 years and 2.2 ± 1.1% at 10 years. CI of xerostomia/dental decay was 2.6 ± 1.3% at 5 years and 4.9 ± 2.1% at 10 years. CI of cardiac disease was at 2.3 ± 0.9% at 5 years and 4.4 ± 1.5% at 10 years. CI of infertility was 6.5 ± 1.6% at 5 years and 9.4 ± 2.1% at 10 years. CONCLUSION: Survivors of AYA lymphoma have a high incidence and diverse presentation of late effects. IMPLICATIONS FOR CANCER SURVIVORS: AYA lymphoma survivors should be educated about their risks of late effects and offered screening and follow-up when appropriate.
Authors: Sharyl J Nass; Lynda K Beaupin; Wendy Demark-Wahnefried; Karen Fasciano; Patricia A Ganz; Brandon Hayes-Lattin; Melissa M Hudson; Brenda Nevidjon; Kevin C Oeffinger; Ruth Rechis; Lisa C Richardson; Nita L Seibel; Ashley W Smith Journal: Oncologist Date: 2015-01-07
Authors: Daniel S Olsson; Eva Andersson; Ing-Liss Bryngelsson; Anna G Nilsson; Gudmundur Johannsson Journal: J Clin Endocrinol Metab Date: 2014-11-06 Impact factor: 5.958
Authors: Gemma Gatta; Giulia Zigon; Riccardo Capocaccia; Jan Willem Coebergh; Emmanuel Desandes; Peter Kaatsch; Guido Pastore; Rafael Peris-Bonet; Charles A Stiller Journal: Eur J Cancer Date: 2009-02-21 Impact factor: 9.162
Authors: Leslie L Robison; Gregory T Armstrong; John D Boice; Eric J Chow; Stella M Davies; Sarah S Donaldson; Daniel M Green; Sue Hammond; Anna T Meadows; Ann C Mertens; John J Mulvihill; Paul C Nathan; Joseph P Neglia; Roger J Packer; Preetha Rajaraman; Charles A Sklar; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544